Clinical Trial: A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants

U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07554365) titled 'A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants' on April 02.

Brief Summary: AN01 is a selective small-molecule dual inhibitor of phosphodiesterase 3 and 4 (PDE3/4).

As a potential new therapy for COPD, AN01 is expected to serve either as a monotherapy for COPD or as adjunctive therapy to current inhaled standard treatments, potentially generating synergistic complementary effects in patients requiring additional therapeutic options.

The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of AN01 in healthy p...